Background
This study aimed to investigate the rate of early improvement in ejection fraction (EF) within 21 - 60 days among patients with cardiomyopathy who were provided with a wearable cardioverter defibrillator (WCD).
Methods
This was a retrospective study of patients who received a WCD at our institution to determine the rate of improvement in left ventricular EF (LVEF) to ≥ 35-40%. Among 990 patients who received a WCD during the study period, 101 had an echocardiogram performed during the subsequent 21 - 60 days. Patients were stratified according to their initial EF, as well as age, gender, number of heart failure medications, and ischemic vs. nonischemic cardiomyopathy. Multivariate logistic regression analysis was performed to assess the influence of these variables on the subsequent improvement in EF.
Results
There were 39 patients who had improvement in their EF to ≥ 35-40%. The only significant predictor of EF recovery was the initial EF. There was a direct correlation between initial EF category and the likelihood of improvement in EF. For every unit increase in initial EF category, the odds of improvement increased 1.73 times (95% confidence interval (CI): 1.22 - 2.45). Age (P = 0.20), gender (P = 0.10), ischemic cardiomyopathy (P = 0.40), and number of heart failure medications at the time of WCD placement (P = 0.26) were not significant predictors of improved LVEF.
Conclusions
This study showed a rate of improvement in EF to ≥ 35-40% of 39% within 21 - 60 days of placement of a WCD among patients with both ischemic and nonischemic cardiomyopathy. The only significant clinical predictor of EF improvement was initial EF.
Background: Methicillin-resistant
Staphylococcus aureus
(MRSA) infective endocarditis (IE) is associated with high morbidity and mortality. Current IE guidelines recommend transesophageal echocardiogram (TEE) over transthoracic echocardiogram (TTE) to diagnose infective endocarditis. Management of IE in people who inject drugs (PWID) in many medical centers is mainly conservative with prolonged intravenous antibiotics. Cardiac valve replacement in these patients remains controversial, given the high risk of reinfection. This study’s purpose is to evaluate whether obtaining sequential TEE after TTE in PWID with MRSA native-valve IE changes the management plan in these patients.
Methods: A retrospective cohort of patients who are 18 years of age or older and inject drugs with definite MRSA IE between 2013 and 2019 were studied. Their echocardiographic reports and overall management plans were reviewed.
Results: One hundred and twenty-six patients met the inclusion criteria. TTE was performed in 121 patients and, of these patients, 69 (57%) had detectable valvular vegetations while 52 (43%) did not. Of the 52 patients with a negative TTE, 44 underwent TEE, 28 (53%) of which showed vegetation. A total of 18 (14%) patients underwent surgery. Of these, six (33%) patients had a positive TTE only, with no subsequent TEE. Ten (56%) patients had both a positive TTE and TEE, and two (11%) patients had a negative TTE but positive TEE.
Conclusion: In this retrospective cohort, obtaining a sequential TEE after a TTE in PWID with proven MRSA native IE by modified Duke’s criteria changed the management plan in two patients. The decision to perform a TEE in these patients needs to be individualized. Larger studies are needed to better evaluate the role of TEE in this patient population.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.